


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Biogen (omaveloxolone)	All Wales Inherited Metabolic Disease Service
Patient/carer groups	All Wales Therapeutics and Toxicology
Ataxia UK	Centre
Beacon	Allied Health Professionals Federation
Brain and Spine FoundationBrain Charity	 Board of Community Health Councils in Wales
	British National Formulary
D. I. A. THE	
	•
Gene People	Department of Health - Northern Ireland Department of Hea
Genetic Alliance UK	Healthcare Improvement Scotland
Neurological Alliance	Medicines and Healthcare products
Scoliosis Support & Research	Regulatory Agency
South Asian Health Foundation	National Association of Primary Care
Specialised Healthcare Alliance	National Pharmacy Association
	Neurological Alliance of Scotland
Healthcare professional groups	NHS Confederation
 Association of British Neurologists 	Scottish Medicines Consortium
British Association of Neuroscience	Wales Neurological Alliance
Nurses	Welsh Government
British Geriatrics Society	Welsh Health Specialised Services
British Neuropathological Society	Committee
British Society for Blood and Marrow	
Transplantation	Possible comparator companies
British Society of Rehabilitation	None
Medicine	
Chartered Society of Physiotherapy	Relevant research groups
Institute of Neurology	Brain Research UK
National Neurosciences Advisory	Cochrane Multiple Sclerosis and Rare
Group	Diseases of the Central Nervous
Primary Care and Community	System Group
Neurology Society	Genomics England
Royal College of General Practitioners	MRC Clinical Trials Unit
Royal College of Nursing	National Institute for Health Research
Royal College of Occupational	Oxford-Harrington Rare Disease Centre
Therapists	



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine 	UCL Queen Square Institute of Neurology Associated Public Health groups
UK Clinical Pharmacy Association	Public Health WalesUK Health Security Agency
<u>Others</u>	
 Department of Health and Social Care NHS England Oxford Ataxia Centre 	
 Paediatric Ataxia Centre, National Hospitals for Neurology and Neurosurgery 	
Sheffield Children's Centre	
 The London Ataxia Centre, National Hospitals for Neurology and 	
Neurosurgery	
The Sheffield Ataxia Centre,	
Department of Neurology, Royal Hallamshire Hospital	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).





All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.